Join
Live feed
·
PRReleasevia Quantisnow
UroGen Pharma Ltd. logo

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

ByQuantisnow·Wall Street's wire, on your screen.
URGN· UroGen Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track URGN (UroGen Pharma Ltd.) and more on Quantisnow.